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Abstract: Alzheimer’s disease and vascular dementia are estimated to be the most common causes
of dementia, although mixed dementia could represent the most prevalent form of dementia in
older adults aged more than 80 years. Behavioral disturbances are common in the natural history
of dementia. However, so far, there is a paucity of studies that investigated the causal association
between behavioral psychological symptoms of dementia and dementia sub-types, due to the high
heterogeneity of methodology, study design and type of clinical assessment. To understand the scant
evidence on such a relevant clinical issue, it could be hypothesized that a new shifting paradigm could
result in a better identification of the relationship between behavioral disturbances and dementia.
This narrative review provides an update of evidence on the behavioral patterns associated with
different dementia sub-types and offers a potential future perspective as common ground for the
development of new translational studies in the field of behavioral disturbances in dementia and the
appropriateness of psychoactive treatments.
Keywords: vascular dementia; Alzheimer’s disease; mixed dementia; behavioral disturbances
clusters; antipsychotics
1. Introduction
Dementia is expected to affect approximately 42.3 million people worldwide by 2020 [1] and
Alzheimer’ s disease (AD) is estimated to be the first cause of dementia whereas vascular dementia
(VaD) is estimated to be the second most common type, with at least 20% of all cases of dementia [2].
However, with aging, the mixed dementia (MixD) subtype is projected to be the most prevalent type of
dementia, especially in older adults aged 80 years and more, ranging from 20–25% to 35% of all cases
of dementia. In line with that and from a neuropathological standpoint, Jellinger et al. [3,4] reported
that autopsies on oldest old patients aged more than 85 years confirmed the high prevalence of mixed
brain neurodegenerative conditions, including MixD, synucleinopa-thy, TDP-43 protein accumulation,
and astrogliopathy.In a wider conceptual framework, vascular cognitive impairment (VCI) could be
considered the first clinical manifestation of VaD, as proposed by Sachdev [5] in 1999, and it includes a
series of cognitive deficits of vascular origin. Later, O’Brien et al. [6] broadened this original conceptual
framework to all forms of cognitive impairments associated with any cerebrovascular disease and/or
vascular brain injury. Wiesmann et al. [7] defined VCI as a cognitive deficit that included at least
a single impaired cognitive domain without any impairment of activities of daily living (ADL) [8].
Moreover, VCI could represent the early sign of different clinical conditions, ranging from post-stroke
dementia, hypoperfusion dementia, multiple microinfarcts to MixD. Several recent studies pointed
out that vascular risk factors are associated with different forms of dementia and that most forms of
dementia could be considered a true extension of the inner vascular disease [9].
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In addition, the presence of behavioral and psychological symptoms (BPSD) may be associated
with the early onset of VCI, although with ambiguous evidence. In particular, the pattern of distribution
of behavioral disturbances in VCI showed that apathy, irritability/agitation, depression, anxiety and
eating disorders, were the most prevalent symptoms [10].
Indeed, growing evidence indicates that BPSD are common in patients with dementia across the
natural history of the disease, representing a wide spectrum of non-cognitive symptoms. Their presence
is considered a predictor of poorer clinical outcomes [11], including multimorbidity, disability, poorer
quality of life, higher caregivers’ burden [12,13], and institutionalization [14]. In the huge spectrum of
behavioral disturbances associated with dementia, it is generally accepted that a series of neurotic
symptoms (anxiety, depression, irritability, psychomotor agitation), psychotic symptoms (delusions,
hallucinations), apathy, disinhibition, aberrant motor behavior and circadian rhythms disturbances
(sleep disorders and eating abnormalities) [15] may vary in intensity and clusters according to the
natural history of brain neurodegeneration.
In particular, it could be hypothesized that the clustering and patterns of BPSD may vary on the
basis of the etiopathogenetic of dementia. As a result, neurobehavioral disturbances may change in
patterns and severity according to the deficits of specific neuroanatomic circuits and/or disconnections.
Indeed, patients with VaD may early experience depression, that is generally characterized by a higher
clinical burden of symptoms, with reduced antidepressant response. In line with these notions, it could
also be conceived that specific BPSD patterns could be associated with different dementia sub-types on
the basis of a common neuroanatomic background, although the multifactorial origin of behavioral
disturbances makes this putative association a real challenge.
2. Behavioral Disturbances and Dementia Sub Types: Vascular Dementia (VaD), Alzheimer’s
Disease (AD) and Mixed Dementia (MixD)
So far, there has been a paucity of studies that investigated the causal association between BPSD and
dementia sub-types, due to the high heterogeneity of study design, with methodology and population
biases and the lack of systematic clinical assessments (see Table 1 for summary). Sultzer et al. [16]
investigated the patterns of behavioral disturbances in patients with AD, that included a set of patients
comorbid for brain vascular disease and compared them to those affected by VaD. The results showed
that VaD patients had increased blunted affect, depression, emotional withdrawal, motor retardation,
decreased motivation, anxiety and somatic concerns. In addition, VaD was associated with higher
severity of behavioral symptoms and lower response rate to usual anti-depressant and/or psychoactive
treatments. An inverse correlation between the cognitive status (as measured by MMSE) [17] and
behavioral disturbances (as measured by Neurobehavioral Rating Scale) [18] was also reported.
Santos et al. [19] showed that patients with VaD experienced apathy, irritability, anxiety, depression
and disinhibition that were the most common neuropsychiatric symptoms (NPS), compared to patients
with MixD. Moreover, this disrupting behavioral cluster occurred in the early stage of VaD natural
history, although no association with the duration of the disease was observed.
From a pathogenetic view point, an impairment of the neuro-affective circuits, due to the
progressive neurodegeneration, could be hypothesized.
Hargrave et al. [20] compared the type and clusters of behavioral symptoms in AD dementia
subtype compared to VaD subtype. A decreased affect/withdrawal and psychomotor retardation
were the most prevalent and disrupting behavioral symptoms in patients with VaD. Although the
presence of white matter disease (WMD) was considered responsible for the behavioral disruption,
the severity of psychomotor retardation in VaD patients was not correlated with the degree of WMD
cortical burden [21,22].
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Table 1. Summary of the evidence on the different neuropsychiatric symptoms associated with vascular
dementia (VaD), Alzheimer’ s disease (AD) and mixed dementia (MixD) sub types.
Authors (Year) Study Design StudyPopulation N Results Reference
Sultzer et al.
(1993)
Observational VaD versus
AD
American older
adults 104
Patients with VaD had more
severe behavioural retardation,
depression and anxiety.
[16]
Hargrave et al.
(2000)
Observational on patient
with VaD versus AD.
American older
adults 378
Decreased affect/withdrawal and
psychomotor retardation were the
most prevalent symptoms in
patients with VaD.
[20]
Saz et al. (2009) Cross sectional VaD versusAD
Spanish (age
>55 yrs) 4.803
AD patients had a higher rate of
“negative-type” (anhedonia,
psychomotor retardation).
VaD patients reported increased
“affective-type” symptoms.
[23]
Ballard et al.
(2000)
Prospective VaD versus
AD
English older
adults 184
Anxiety and depression were
more common in patients with
VaD.
[26]
Echávarri et al.
(2013)
Retrospective VaD versus
AD
Spanish older
adults 80
Agitation, depression and anxiety
in both groups no significance
differences.
[29]
Groves et al.
(2000)
Retrospective VaD, versus
AD
American
(mean age
76 yrs)
517 VaD patients are more depressedand functionally impaired. [30]
Santos et al.
(2018)
Retrospective VaD versus
MixD
Brazilian older
adults (>60 yrs) 53
Patients with VaD had more
apathy, irritability, anxiety and
depression. Association between
NPS and mild to moderate
dementia.
[19]
Anor et al.
(2017)
Observational VaD versus
AD versus MixD
Canadian older
adults 180
1. VaD patients had higher
agitation sleep disturbances,
depression and aberrant
motor behaviors.
[27]
Caputo et al.
(2008)
Observational VaD versus
AD and Lewy Body
dementia
Italian older
adults 921 VaD had less disrupted behaviors. [25]
D’Onofrio et al.
(2012) Observational
Italian older
adults 302
AD patients show increased
agitation/aggression and
irritability/lability.
[28]
Sadak et al.
(2014)
Retrospective VaD, Lewy
body dementia,
Frontotemporal dementia
versus AD
Americans
(>65 yrs) 3768
Prevalence of targeted behavioral
and psychological symptoms
(BPSD) varied according to the
aetiology and severity
of dementia.
[24]
It is noteworthy that the study underpinned the need to include the contribution of additional
neurobiological factors to better understand the relation between infarct locations and the progression
of affective changes in dementia.
Moreover, Saz et al. [23], in a large population-based sample, analyzed the different behavioral
patterns of AD patients compared to those with VaD. In particular, AD patients had a higher
rate of “negative-like” symptoms such as anhedonia, and psychomotor retardation whereas VaD
patients reported increased “affective-like” symptoms. In addition, psychotic symptoms were most
common in VaD dementia while AD patients experienced irritability, dysphoria, delusions, anxiety,
and misperceptions.
Sadak et al. [24] compared the prevalence of four BPSD clusters (agitation, aggression, depression,
anxiety, irritability and dysphoria) across dementia etiologies, using AD as the reference type of
dementia. The main findings indicated that the prevalence of target BPSD varied according to etiology
and the severity of dementia and, namely, AD patients had the lowest prevalence of selected BPSD,
while overlapping AD and VAD did not display any higher rate of BPSD patterns.
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In keeping with that, Caputo et al. [25] reported a decreased rate of anxiety in VaD patients
as compared with patients with AD patients, but no difference in terms of depression and apathy
was observed between these two types of dementia. Moreover, Ballard et al. [26] indicated that
depression, anxiety and⁄or apathy were the most common behavioral disturbances associated
with VaD. Furthermore, Anor et al. [27] compared the behavioral patterns associated with AD,
VaD and MixD, respectively, indicating that patients with VaD showed increased psychomotor
agitation, sleep disturbance and depression. In contrast, D’Onofrio et al. [28] reported increased
agitation/aggression and irritability/lability in patients with AD compared to VaD patients.
Echávarri et al. [29] did not observe any difference in the behavioral presentation according to
specific dementia sub-types.
Groves et al. [30] observed that patients with VaD were more likely to experience long-standing
depression with functional impairment on a long-term observational period, although AD patients
were also observed to experience some degree of sleep disorders and depression according to the
neurodegenerative trajectory.
In line with all the aforementioned notions, it could be hypothesized that patients with VaD have
highly disrupted behavioral disturbances compared to AD and/or MixD patients.
Namely, the putative association of specific behavioral clusters to VaD seems to include
psychomotor retardation, anxiety/depression with guilt and somatic concern, early insomnia and
general somatic complains [31], although the speculative nature of this association limited the
generalizability of the findings.
3. Neuroanatomic Findings Between Behavioral and Psychological Symptoms (BPSD) and
Dementia Sub-Types (VaD, AD and MixD)
The use of neuroimaging allows the identification of specific neuroanatomic circuits that may
be potentially involved in the onset of disruptive behaviors associated with different dementia
subtypes. The impairment of the neuroanatomic circuits, due to progressive neurodegeneration
refers to the pathological changes in the frontal-subcortical pathways and frontal lobe hypoperfusion,
along with the dysfunction of dopaminergic, serotonergic, and noradrenergic neurotransmission.
Alterations of these systems are reported to be the pathophysiological background for various behavioral
disturbances [32,33]. In addition, focal brain injury or white matter disease, periventricular white
matter hyperintensities (WMH), small vessel disease and interruption of subcortical circuit have been
also considered the pathogenetic vulnus for the onset of behavioral disturbances in VaD or MixD
dementia [34].
However, Brown et al. [32] showed that the older age itself was an indirect risk factor for
the presence of WMH signals as a result of vascular changes associated with comorbid medical
clinical conditions.
Moreover, Anor et al. [27] observed that VaD patients had a lower rate of WMH frontal cortical
burden compared to patients with AD or MixD but this reduced WMH burden was associated
with higher disrupted behaviors, including irritability. In contrast, the presence of higher frontal
WMH burden was associated with decreased behavioral disturbances, indicating the loss of synaptic
connections in the frontal lobe, as a result of WMH insults, the neuroanatomic leakage responsible for
the aforementioned symptomatology association.
Moreover, a significant trend between increased behavioral disturbances and higher WMH
right frontal deposition was observed. In particular, AD patients with higher right frontal lobe WM
deposition experienced an increased rate of psychotic symptoms such as delusions, compared to
those patients with MixD. However, VaD patients with reduced left lobe WMH burden experienced a
decreased rate of neurotic symptoms such as irritability.
Ting et al. [35]. observed that the presence of cortical microinfarcts and small vessels disease was
associated with the onset of psytha chosis in AD patients, although the magnitude of this association
has not been clearly defined, due to the multifactorial origin of behavioral disturbances and the
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heterogeneous clinical phenotype of old age patients with dementia. Indeed, older adults generally
had comorbidity and polypharmacy, that may represent important potential confounders for the
appropriate diagnosis and clinical management of BPSD.
In keeping with that, WMH was also reported to be a contributing factor for psychosis and it
was suggested that the integrity of small vessels of both cortical and subcortical layers was a key
determinant factor for the development of psychosis. Similarly, focal frontal brain injury was observed
to be associated with behavioral disturbances, including disinhibition and apathy [36]. In particular,
apathy was associated with anterior cingulate atrophy [37] while periventricular WMH burden was
associated with hallucination, depression and anxiety in both VaD and AD [38].
Recently, a new theoretical framework included white matter disruption by virtue of altered
connectivity of WM network, especially in the frontal and parietal lobes as key determinants of both
cognitive and behavioral disturbances in VaD [39].
The main neuroanatomic circuits involved in the onset of BPSD are illustrated in Figure 1.
Figure 1. BPSD overlap and patterns according to specific dementia sub-types on the basis of the
altered neuroanatomic circuits.
It is noteworthy that a correlation between polymorphisms of apolipoprotein E (APOE) and
low-density lipoprotein receptor-related protein gene (LRP) and BPSD patterns in AD and VD dementia
has been recently observed. Namely APO epsilon 4 frequency of both AD and VD patients experiencing
BPSD was higher than controls. This finding underpinned some similarity between the pathogenesis
of AD and VD sub-types, including the pathogenesis of BPSD patterns where psychotics symptoms
showed a substantial correlation with APO E epsilon 4 in both AD and MixD sub-types. Indeed,
this genetic carriage may promote the deposition of fibrillar amyloid β protein, affecting the amyloid β
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clearance, with the increase formation of neurofibrillary tangles. In contrast no difference was observed
between LPR carriage in AD and VD sub-types [40].
4. Antipsychotic Use across Dementia Sub-Types (VaD, AD Versus MixD)
The use of antipsychotics is common in the natural history of dementia to treat behavioral
disturbances, although their use may cause additional morbidity and disability in patients
with pre-existing clinical vulnerability. It is well known that antipsychotics are associated with
worsening cognitive performance, disability, increased caregiver burden, unfavorable clinical
outcomes, including falls, anticholinergic burden and delirium [41–44], hypotension, sedation, and
extrapyramidal symptoms. The 2016 American Psychiatric Association (APA) Practice Guidelines
provided recommendations for the treatment of agitation or psychosis in patients with dementia,
suggesting a comprehensive, person-centered, non-pharmacological approach [45].
In line with that, non-pharmacological interventions for behavioral disturbances should be
advocated as the first line of therapeutic interventions. In particular, a recent metanalysis showed
the clinical benefit of different non-pharmacological approaches on functional status in patients with
moderate to advanced dementia. Namely, these interventions included exercise therapy, light therapy,
music therapy, massage therapy and multi component therapy [46]. Similarly, Abraha et al. [47].
provided an extensive overview on non-pharmacological interventions to treat BPSD in older patients
with dementia, indicating that music therapy and behavioral management techniques were effective in
reducing BPSD. However, the heterogeneous definition and application of the same type of intervention
affected the generalization of the findings.
In line with that, Wang et al. [48] categorized three main types of non-pharmacological interventions
including, respectively, sensory, cognition and movement-oriented approaches to assess the quality of
evidence in treating BPSD in patients with dementia. Indeed sensory-orientated interventions reported
the most consistent clinical benefits; however, the ability of the person with dementia to fulfill the
requests and to participate successfully in the approach underpinned how tailored interventions are
needed for these patients, on the basis of their individualized cognitive abilities.
Moreover, Caspar et al. [49] developed a unifying heuristic model to improve the understanding
of effective non-pharmacological treatment modalities for BPSD. The identification of the caring
environment, the development of care skills and maintenance, and the individualization of care
represented the key relevant interventions associated with reduced BPSD as well as with increased
clinical benefit for those highly vulnerable patients.
Antipsychotics are recommended within this approach as appropriate for the treatment of agitation
and other NPS in patients with dementia, when symptoms are severe, threatening, and/or cause
significant patient distress. However, at present, no medication has been approved by the United
States (US) Food and Drug Administration (FDA) for the treatment of NPS associated with AD.
In addition, the US Food and Drug Administration issued a warning on the increased incidence of
adverse cerebrovascular events in patients treated with antipsychotics as an off-label treatment for
behavioral disturbances in dementia [50].
So far, some body of evidence indicates that atypical antipsychotics displayed a better safety and
tolerability profile than typical antipsychotics [51–53]. Wooltorton et al. [54] and Mowat et al. [55],
respectively, claimed that, although the inappropriate use of antipsychotic medications is a critical
issue in persons with dementia, the identification of the clinical benefit to risk ratio for the use of
antipsychotics in dementia is highly recommended to tailor the therapeutic interventions on an
individualized basis. Up to date, there is scant evidence on the antipsychotic prescribing treatment
patterns and burden of behavioral disturbances in patients with different dementia sub-types and this
is especially true in the prescribing patterns for VaD and MixD. Namely, Moretti et al. [56], assessed
the role of olanzapine in patients with subcortical VCI and showed its effective and safety profile on
anxiety, with neglected side effects including sedation, postural instability, and postural hypotension.
Moreover, no serious anticholinergic effect was observed.
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Alfonso et al. [57] showed that risperidone was an effective treatment for both VaD and MixD
sub-types and it is, up to date, the sole direct comparison between specific antipsychotic prescribing
patterns in different dementia sub-types. The use of risperidone at a mean dose of 1.6 mg/day for
6 months was of clinical benefit in the treatment of aggression, psychomotor agitation and psychosis.
A reduction of apathy/indifference and depression/dysphoria was also observed.
Risperidone was considered to be a well-tolerated drug with respect to the cardiovascular profile
and extrapyramidal symptoms, with hypotension and sedation as mild reported side effects. Table 2
illustrates the few evidence on different antipsychotic prescribing patterns on the basis of specific
dementia sub-types. Notwithstanding that, the evidence is scant and fragmentary and does not allow
any categorization of behavioral disrupted clusters in the presence of specific forms of dementia.
Suh et al. [58] compared haloperidol with risperidone in patients with AD, VD and MixD,
indicating that both antipsychotics were of clinical benefit in reducing BPSD. However, risperidone
better improved patient’s clinical global impression (Clinical Global Impression of Change scale CGI-C),
with a safer profile in terms of reduced risk of antipsychotic-induced parkinsonism.
Recently, Davies S et al. [59] developed an overarching guide to sequential use of psychoactive
drugs, including antipsychotics, in order to treat agitation and aggression in AD, Mix D and VD.
This evidence-based algorithm was weighed on the basis of safety, tolerability, efficacy, easy to use,
time to onset of clinical effect and strength of evidence. In addition, titration schedules, adjustment
for patient’s frailty and baseline assessment and/or discontinuation of potentially exacerbating drugs
were also considered. It is noteworthy that risperidone, quetiapine and aripiprazole were the most
recommended antipsychotics in the over-mentioned types of dementia. Namely, risperidone had the
strongest evidence for the treatment of BPSD symptoms in AD and MixD [60–63], although it carries
higher cardiovascular and metabolic risks.
Table 2. Antipsychotic prescription patterns according to specific dementia sub-types (VaD, AD
and MixD).
Type of
Antipsychotics Type of Dementia Mean Dose
Observation
Frame
Targeted
Symptoms Side Effects References
Olanzapine Vascular cognitiveimpairment (VCI) 2.5–5 mg/day 6 months Anxiety
somnolence,
postural
instability, and
postural
hypotension.
Moretti et al.
[56]
Risperidone VaD, AD, Mixed 1–2 mg/day 6 months
Aggression,
agitation, apathy,
depression
dysphoria.
Hypotension
sedation,
paraesthesia.
Alfonso et al.
[57]
Risperidone VaD, AD, Mixed 0.95 mg/day 12 weeks
Aggression,
psychotic
symptoms
Somnolence,
urinary tract
infections.
Brodaty et al.
[59]
Aripiprazole AD, VaD, MixD 2.5–10 mg/day 10 weeks
Agitation,
psychotic
symptoms
Cerebrovascular
adverse events.
Mintzer et al.
[65]
Risperidone vs.
Haloperidol VaD, AD, Mixed 1–1.5 mg/day 18 weeks
Aggression,
anxiety
(Risperidone)
Extrapyramidal
symptoms
(Haloperidol).
Suh et al.
[58]
Quetiapine AD, VaD, Lewybody dementia 300 mg/day 12 weeks
Psychotic
symptoms NA
Cheung et al.
[64]
Quetiapine has a considerable weaker evidence for the treatment of BPSD in AD and MixD
types, compared to risperidone. However, a previous metanalysis [64] showed the clinical benefit of
quetiapine compared to placebo on overall clinical patient’s improvement and on generalized anxiety
disorder. This clinical profile makes quetiapine alongside aripiprazole as a first line option for the
proposed treatment algorithm.
Moreover, aripiprazole was included as an alternative to quetiapine for the treatment of psychosis
in patients AD and MixD [65].
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It is noteworthy that haloperidol was excluded from the first line of recommended antipsychotics
in the proposed algorithm due to safety concerns, as recently reported in a retrospective study of
nursing home resident with AD and MixD sub-types [66,67], where conventionally antipsychotics
significantly increased the risk of both mortality and hip fracture. In line with that, the authors
speculated that the treatment of patients with AD and/or MixD, experiencing agitation and aggression
with the aforementioned antipsychotics may be of some clinical benefit. However, the appraisal of
this evidence does not involve systematic reviews but it is based on reviewer’s synthesis of drug’s
acceptability, applicability and easy to use.
5. Discussion and Conclusions
So far, few studies have investigated the behavioral disrupted patterns associated with different
dementia sub-types along with the specific antipsychotics prescribing patterns and the present review
provides an updated evidence on this challenging and underestimated clinical issue.
In particular, the main findings showed that VaD patients are more likely to experience a
specific neuropsychiatric pattern that is characterized by affective behaviors such as depression,
psychomotor retardation, anxiety, apathy and affective withdrawal with a lower response rate to
usual antidepressants [68]. From a clinical viewpoint, it could be hypothesized that apathy and
depression could be considered two overlapping and misleading clinical conditions. In particular,
the appropriate diagnosis of apathy has to date been underreported and undertreated, due to several
pathophysiological and diagnostic pitfalls. In turn, the inadequate identification of apathy, especially
in VaD patients could, at least partially explain the inherent ineffectiveness of antidepressants therapy
in those patients [69].
It is generally accepted that several neurodegenerative diseases may be associated with different
behavioral disturbances; however, so far, few studies have examined differences in BPSD between
dementia sub-types and the results have been quite equivocal [70–77].
However, the available evidence is too limited to gather a comprehensive evaluation of the
neuroanatomic pathways that may define the onset of clustered BPSD in specific dementia sub-types.
Moreover, this same limitation makes better understand how the identification of appropriate
prescribing antipsychotics treatments for selected behaviors underlying a specific sub-type of dementia
has been unfeasible up to now.
In line that, a number of issues in assessing the wide spectrum of BPSD in dementia may count
for the paucity in results among studies, making the evidence even more controversial.
It is noteworthy that the spectrum of behavioral disturbances in dementia tends to fluctuate over
time and each BPSD domain, in terms of pattern, clusters, persistence and intensity over time may be
highly individualized on the basis of patients’ clinical phenotype and of the multifactorial origin of
disrupted behaviors themselves.
Similarly, this huge heterogeneity in the clinical presentation of behavioral disturbances may
be the result of different underlying neurobiological correlates, including the specific form of brain
neurodegeneration and its related stage. Additionally, the presence of comorbidity, the individual
burden and severity of vascular cerebral load, the failure of synaptic connections and neurotransmission
and the ageing process itself may count for additional multicomponent factors, adding further degrees of
clinical complexity to the natural history and clinical trajectory of BPSD in different dementia sub-types.
Moreover, although it has been estimated that a higher percentage of patients with dementia
experience BPSD over the course of their illnesses, the low epidemiological rate of BPSD in dementia
claims for a significant underreporting and a underdiagnosis [68]. This turns out to be especially true
for the identification of different pathways to BPSD in different dementia sub-types.
Furthermore, on the one hand, the rigorous and longitudinal assessment of behavioral profiles in
dementia could enable the development of more effective treatments, assessing the appropriateness
and tailored use of antipsychotics as well. On the other hand, the current failure in the identification
of different patterns for behavioral clusters, according to different forms of dementia, may unmask a
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major conceptual pitfall. In line with this assumption, this narrative review seems to indirectly confirm
that the co-occurrence of multiple neuropathological disorders is common in persons with dementia,
especially with advancing age, and this paradigm shift could be applied to the understanding of
behavioral disturbances associated with dementia as well.
So far, the underlying neuropathology of dementia has been poorly established and it could differ
significantly from the pathogenesis implied by the clinical diagnosis. Thus, it could be hypothesized
that the mere categorization of specific dementia sub-types may serve as a useless platform for the
development of studies that are expected to unravel the pathogenesis of dementia, its natural course,
including the spectrum of behavioral disturbances.
An alternative approach is to focus on common molecular mechanisms rather than single specific
disease processes that can lead to brain neurodegeneration. In keeping with that, Mallucci et al. [78]
developed the unfolded protein theory according to which a common misfolded protein defect primarily
occurred in the endoplasmatic reticulum of neurons cells, spreading in between and through cells
and ultimately fostering the process of brain neurodegeneration. This theory could be considered an
umbrella for different neurodegenerative disorders, including Alzheimer’s disease, various tauopathies,
prion disease, idiopathic Parkinson’s disease and the sporadic amyotrophic lateral sclerosis. Whatever
the exact mechanism is, the resultant cell-to-cell spreading may favor the metabolic derangement of
neurons and astroglia’s cells, boosting brain cellular shutdown. This same detrimental mechanism may
be at the basis of the major driving force behind both brain neurocognitive degeneration and behavioral
disturbances, due to the sharing of neuroanatomic circuits deficits and neuronal/neurotransmitters
disconnections [79].
In line with this notion, it could be hypothesized, although highly speculative in nature, that
the aforementioned common molecular background for brain neurodegeneration could be also
common ground for behavioral disturbances associated with dementias, in terms of pattern clusters
and intensity, irrespective of the categorization in single dementia sub-types. Similarly, a fine and
unexplored “switching on/off” mechanism may modulate the onset and progression of both dementia
and behavioral disturbances, drawing substantial different patterns across the natural history of
brain neurodegenerations.
Thus, in an era of crisis for the treatment of dementia and in presence of scant evidence on the
appropriateness of psychoactive treatments for such a huge spectrum of behavioral disturbances,
the pursuit of a shifting paradigm for BPSD in dementia could offer a new field of research that has
real translational value to provide better quality of care in the near future.
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Abbreviations
VaD vascular dementia
MixD mixed type dementia
VCI vascular cognitive impairment
ADL activities of daily living
BPSD behavioral and psychological symptoms of dementia
NPS neuropsychiatric symptoms
AD Alzheimer’s disease
MMSE mini-mental state examination
WMD white matter disease
WMH white matter hyperintensities
BEHAVE-AD-K Behavioral Pathology in Alzheimer’s Disease Rating Scale, Korean version
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